By Joe Messa
Since late last year, several pharmaceutical companies have been slowly recalling various lots of blood pressure medications containing valsartan, irbesartan, or losartan. The recalled drugs are believed to potentially contain an impurity called N-nitrosodiethylamine (NDEA). NDEA is a known animal and probable human carcinogen (Group 2A) most often found in tobacco smoke. The medications involved […]
Continue readingBy Joe Messa
Tris Pharma, Inc., a New Jersey based pharmaceutical manufacturer, has issued a voluntary recall of infant ibuprofen that may contain higher concentrations than noted on the bottle, leading to potential risks in infants. The impacted lots of medication were sold to a distributor that supplies retailers, including CVS, Walmart, and Family Dollar. Retailers and wholesalers […]
Continue readingBy Joe Messa
The US Food and Drug Administration (FDA) announced this week that certain drugs used to treat diabetes have recently been linked to cases of a rare, flesh-eating genital infection. The affected medications are sodium-glucose cotransporter-2 (SGLT2) inhibitors, used to treat Type 2 Diabetes. More than a dozen drugs will have to include warnings of this […]
Continue readingBy Joe Messa
As far as pharmaceutical giants are concerned, AbbVie might not be a household name, but the company’s blockbuster drug, Humira, certainly is. Humira is an immunosuppresive approved to treat arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Recently, the United States Food & Drug Administration (FDA) slammed the Chicago-based pharmaceutical company for not […]
Continue readingBy Joe Messa
On April 25, 2018, the United States Food and Drug Administration (FDA) posted a warning on their website regarding potentially fatal reactions caused by popular seizure and bipolar disorder drug treatment, Lamictal (lamotrigin). The FDA warning described a rare but serious reaction involving the immune system. The drug can excessively activate the immune system to […]
Continue readingBy Joe Messa
On Tuesday, January 2, 2018, The United States Food & Drug Administration (FDA) issued a Class I recall of Johnson & Johnson Agilis Steerable Introducer Sheath valve devices. The recall includes about 110 heart devices distributed between January 1 and May 5. A Class I recall is the strictest recall classification issued by health regulators, […]
Continue readingBy Joe Messa
EpiPens – prescription epinephrine injections used to treat severe allergic reactions – were recently the subject of controversy after drug company Mylan NV raised prices of the lifesaving pens 600% overnight. A year later, the pens are the subject of a new controversy. According to reports filed with the U.S. Food and Drug Administration by […]
Continue readingBy Joe Messa
The United States House of Representatives may vote this week on a bill (House Resolution 1215) that will do grave harm to the rights of citizens to seek justice in court for damages caused by medical malpractice, defective drugs, or defective medical devices. The bill is called the Protecting Access to Care Act and it […]
Continue readingBy Joe Messa
Novo Nordisk, a Danish pharmaceutical company focused on manufacturing medicinal treatments for diabetes, obesity, Haemophilia, growth hormone therapy, and hormone replacement therapy, has been accused in a lawsuit filed on behalf of the Federal Government of engaging in a “white coat marketing scheme” to persuade doctors to prescribe three of its diabetes treatments – NovoLog, […]
Continue reading